Financial Consulate’s Novavax NVAX Stock Holding History

Financial Consulate’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75K	Hold	398	–	–	﹤0.01%	897
2026 Q1	$3.24K	Hold	398	–	–	﹤0.01%	880
2025 Q4	$2.67K	Hold	398	–	–	﹤0.01%	842
2025 Q3	$3.45K	Buy	+398	New	+$3.1K	﹤0.01%	717

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Financial Consulate's NVAX Position: Q2 2026 in Review

Financial Consulate held its Novavax (NVAX) position steady in Q2 2026 at 398 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Financial Consulate first reported a position in NVAX in Q3 2025 and has held it in 4 quarters since. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Financial Consulate held 398 shares of Novavax worth $3.75K as of Q2 2026.
Financial Consulate left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #897 holding.
Financial Consulate first reported a position in Novavax in Q3 2025 and has held it in 4 quarters since.
268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.